nice to see this article come out!!!
the point is the story on the product and its success
the big boys can get in and out when they want
the rest of us are better off getting in at these prices
I had a bottom in , via the charts at around 4.70 It hit 4.9 yesterday
I am not a big chartist so the pros can tell me whats what
but combined that with the volume drying up
we will have traders in now driving the ship
until or unless news is known
THE BIG BOYS HIDE THEIR TRADES BEHIND DAYTRADing
I mean read their article
they said its todays dead cat bounce then cited all the horror ( ok, its true)
AND THEN BAD
then they talk about the companies better outlook
AGAIN, WE ARE SUPPOSE TO BUY BEFORE "WARREN B" GETS IN
However, the consensus estimate suggests that this trend should reverse in the coming year. During the past fiscal year, CYTRX CORP reported poor results of -$0.91 versus -$0.84 in the prior year. This year, the market expects an improvement in earnings (-$0.68 versus -$0.91).
The company's current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. Compared to other companies in
so what if they sold some stock
people want to make money
dont get me wrong I am with you
but by now the game is well known
Sentiment: Strong Buy
So then YOU RODE SRPT DOWN FROM 53 TO 12
WAY TO GO
CAUSE AF WAS A HUGE LONG IN SRPT
while I dont know what they know or dont know here it is:
nced level with close to final numbers being crunched by both parties. Sierra fully anticipates that the deal will now be done and announced within the next 2 months. Sierra forecasts that the share price of CYTR will quickly move up past $12 as big money and institutional buying pours into the stock. Sierra will be replaying the conference call in it’s entirety throughout the week on her site for those that missed it!
"move up past 12pps"
I dont know what trades or when and neither do you
AGAIN,, MANY pump with outrageous statements so that it looks like longs are "Dreaming / foolish"
WE NEED people to short
that is good for the stock
I am long
Investors in CytRx should also know that Dr. Gene Salkind, a highly regarded neurosurgeon, recently filed a 13G showing that he owns just under 3.5 million shares of the company. That is roughly an 8.3 percent ownership stake.
HOME / EXPERT /
Is CytRx Corporation the Next Pharmacyclics?
JAMES RATZ | MORE ARTICLES
DECEMBER 13, 2013
The biggest story this week in biotechnology has been the explosion seen in shares of CytRx Corporation (NASDAQ:CYTR). In fact, the recent move catapults CytRx to one of the top performing biotechnology stocks of 2013, and what’s really interesting is that based on the recent news, CytRx may be on the verge of altering the cancer landscape — much like Pharmacyclics (NASDAQ:PCYC) has done over the past couple of years.
CytRx Corporation is a development-stage biotechnology company developing a potential replacement for doxorubicin, the current standard of care in cancer treatment. The company has developed an improved version of doxorubicin, called aldoxorubicin, which it hopes can be used to treat a variety of cancers including first-line soft tissue sarcoma, second-line soft tissue sarcoma, glioblastoma multiforme, and Kaposi’s sarcoma.
Earlier this week, CytRx announced results from its on-going Phase 2b clinical trial that was evaluating the efficacy and safety of aldoxorubicin in patients with first-line metastatic, locally advanced, or unresectable soft tissue sarcoma. Data from the trial indicated that aldoxorubicin demonstrated between 80 and 100 percent superiority over doxorubicin in progression-free survival as a first-line therapy in advanced soft tissue sarcoma. The median progression-free survival, 6-month progression-free survival and overall response rates all significantly favor aldoxorubicin treatment over doxorubicin. Additionally, there were no serious safety issues seen in the patients.
The Next Pharmacyclics?
In the opening paragraph, I suggested that CytRx may be on pace to become the next Pharmacyclics. There are several reasons why I think this may be the c
well thats what traders are about so no problem
all my real money has been made by holding for some time
my trades have been reallll good and some real bad